Identification of NR1I2 genetic variation using resequencing
- 3 April 2007
- journal article
- pharmacogenetics
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 63 (6) , 547-554
- https://doi.org/10.1007/s00228-007-0295-3
Abstract
The nuclear receptor NR1I2 (also called PXR or SXR) is primarily expressed in mouse and human liver and intestines. Direct activation of NR1I2 occurs in response to a range of xenobiotics, which causes the formation of a heterodimer with the RXR receptor. This heterodimer binds to the nuclear receptor response elements of downstream genes such as ABCB1, CYP2C, and CYP3A. This study determined the extent of NR1I2 variation in three world populations.Keywords
This publication has 35 references indexed in Scilit:
- Polymorphism discovery in 51 chemotherapy pathway genesHuman Molecular Genetics, 2005
- PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysisHuman Mutation, 2005
- PromoLign: A database for upstream region analysis and SNPsHuman Mutation, 2004
- Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoterJournal of Human Genetics, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.2001
- Nomenclature for the description of human sequence variationsHuman Genetics, 2001
- The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during EvolutionMolecular Endocrinology, 2000
- Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A inductionProceedings of the National Academy of Sciences, 1998
- The RXR heterodimers and orphan receptorsPublished by Elsevier ,1995